Cargando…
Efficacy and safety of liraglutide, a once‐daily human glucagon‐like peptide‐1 receptor agonist, in African‐American people with Type 2 diabetes: a meta‐analysis of sub‐population data from seven phase III trials
AIM: To evaluate the efficacy and safety of the glucagon‐like peptide‐1 (GLP‐1) receptor agonist liraglutide in African‐American people with Type 2 diabetes. METHODS: Analyses were performed on patient‐level data from individuals self‐defined as African‐American or non‐African‐American in seven phas...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5248619/ https://www.ncbi.nlm.nih.gov/pubmed/27412701 http://dx.doi.org/10.1111/dme.13185 |